References

  1. Verbeek R, Stoekenbroek RM, Hovingh GK. PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. Eur J Pharmacol. 2015 May 16. [Epub ahead of print]
  2. Giugliano RP, Sabatine MS. Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiology. 2015;65(24):2638-2651.
  3. Abifadel M, Elbitar S, El Khoury P, et al. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep. 2014;16(9):439.
  4. Timms KM, Wagner S, Samuels ME, et al. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum Genet 2004; 114:349-353.
  5. Lowe DC, Vaughan TJ. Rheumatology: a force for change in monoclonal antibodies. Curr Pharm Des. 2015;21(17):2179-2186.
  6. Nelson PN, Reynolds GM, Waldron EE, Ward E, Giannopoulos K, Murray PG. Demystified. Mol Pathol..2000; 53(3):111–117.
  7. Navarese EP, Kołodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia. A systematic review and meta-analysis. Ann Intern Med. 2015; 163:40-51.
  8. Cainzos-Achirica M, Martin SS, Cornell JE, et al. PHPCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment? Ann Intern Med. 2015;163(1):64-65.
  9. US Food and Drug Administration.  Center for Drug Evaluation and Research. The Endocrinologic and Metabolic Drugs Advisory Committee Meeting. June 9, 2015. Briefing Document. BLA 125559. Praluent (alirocumab) injection. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM449865.pdf. Accessed: August 3, 2015.
  10. Endocrinologic and Metabolic Drugs Advisory committee (EMDAC). June 10, 2015.Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM450072.pdf. Accessed: August 3, 2015.
  11. US Food and Drug Administration. FDA approves Praluent to treat certain patients with high cholesterol. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455883.htm. Accessed: July 26, 2015.
  12. PR Newswire. Doctors Would Have 18% of High-Cholesterol Patients take New PCSK9 Inhibitor Drugs Today If FDA Approves Their Use, According to New Data from InCrowd. Available at: http://www.prnewswire.com/news-releases/doctors-would-have-18-of-high-cholesterol-patients-take-new-pcsk9-inhibitor-drugs-today-if-fda-approves-their-use-according-to-new-data-from-incrowd-300098219.html. Accessed: August 1, 2015.
  13. PR Newswire. Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease. Available at: http://www.prnewswire.com/news-releases/amgen-completes-enrollment-in-large-cardiovascular-outcomes-trial-of-repatha-evolocumab-in-patients-with-high-cholesterol-and-clinically-evident-cardiovascular-disease-300094614.html. Accessed: August 4, 2015.
  14. United States National Institutes of Health. Clinical Trials.gov. ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727). Available at: https://clinicaltrials.gov/ct2/show/NCT01663402. Accessed: August 4, 2015.